Mesenchymal stem cells in the treatment of inflammatory and autoimmune diseases in experimental animal models - PubMed

Review

Mesenchymal stem cells in the treatment of inflammatory and autoimmune diseases in experimental animal models

Matthew W Klinker et al. World J Stem Cells. 2015.

Abstract

Multipotent mesenchymal stromal cells [also known as mesenchymal stem cells (MSCs)] are currently being studied as a cell-based treatment for inflammatory disorders. Experimental animal models of human immune-mediated diseases have been instrumental in establishing their immunosuppressive properties. In this review, we summarize recent studies examining the effectiveness of MSCs as immunotherapy in several widely-studied animal models, including type 1 diabetes, experimental autoimmune arthritis, experimental autoimmune encephalomyelitis, inflammatory bowel disease, graft-vs-host disease, and systemic lupus erythematosus. In addition, we discuss mechanisms identified by which MSCs mediate immune suppression in specific disease models, and potential sources of functional variability of MSCs between studies.

Keywords: Animal models; Autoimmunity; Immunotherapy; Inflammation; Mesenchymal stem cells; Mesenchymal stromal cells.

Similar articles

• Shining the light on clinical application of mesenchymal stem cell therapy in autoimmune diseases.

  Jasim SA, Yumashev AV, Abdelbasset WK, Margiana R, Markov A, Suksatan W, Pineda B, Thangavelu L, Ahmadi SH. Jasim SA, et al. Stem Cell Res Ther. 2022 Mar 7;13(1):101. doi: 10.1186/s13287-022-02782-7. Stem Cell Res Ther. 2022. PMID: 35255979 Free PMC article. Review.

• Therapeutic Development of Mesenchymal Stem Cells or Their Extracellular Vesicles to Inhibit Autoimmune-Mediated Inflammatory Processes in Systemic Lupus Erythematosus.

  Sharma J, Hampton JM, Valiente GR, Wada T, Steigelman H, Young MC, Spurbeck RR, Blazek AD, Bösh S, Jarjour WN, Young NA. Sharma J, et al. Front Immunol. 2017 May 10;8:526. doi: 10.3389/fimmu.2017.00526. eCollection 2017. Front Immunol. 2017. PMID: 28539924 Free PMC article. Review.

• Immunomodulatory properties of mesenchymal stem cells and their therapeutic applications.

  Yi T, Song SU. Yi T, et al. Arch Pharm Res. 2012 Feb;35(2):213-21. doi: 10.1007/s12272-012-0202-z. Epub 2012 Feb 28. Arch Pharm Res. 2012. PMID: 22370776 Review.

• Mesenchymal Stem Cells Regulate the Innate and Adaptive Immune Responses Dampening Arthritis Progression.

  Contreras RA, Figueroa FE, Djouad F, Luz-Crawford P. Contreras RA, et al. Stem Cells Int. 2016;2016:3162743. doi: 10.1155/2016/3162743. Epub 2016 Oct 26. Stem Cells Int. 2016. PMID: 27847522 Free PMC article. Review.

• Immunosuppressive properties of mesenchymal stem cells: advances and applications.

  De Miguel MP, Fuentes-Julián S, Blázquez-Martínez A, Pascual CY, Aller MA, Arias J, Arnalich-Montiel F. De Miguel MP, et al. Curr Mol Med. 2012 Jun;12(5):574-91. doi: 10.2174/156652412800619950. Curr Mol Med. 2012. PMID: 22515979 Review.

Cited by

• Evaluation of the Therapeutic Potential of Mesenchymal Stem Cells (MSCs) in Preclinical Models of Autoimmune Diseases.

  Shandil RK, Dhup S, Narayanan S. Shandil RK, et al. Stem Cells Int. 2022 Jul 28;2022:6379161. doi: 10.1155/2022/6379161. eCollection 2022. Stem Cells Int. 2022. PMID: 35935180 Free PMC article. Review.

• The modulation of mature dendritic cells from patients with type 1 diabetes using human periodontal ligament stem cells. An in-vitro study.

  Ashour L, Al Habashneh RA, Al-Mrahelh MM, Abuarqoub D, Khader YS, Jafar H, Awidi AS. Ashour L, et al. J Diabetes Metab Disord. 2020 Aug 12;19(2):1037-1044. doi: 10.1007/s40200-020-00602-4. eCollection 2020 Dec. J Diabetes Metab Disord. 2020. PMID: 33520821 Free PMC article.

• Continuing Effect of Cytokines and Toll-Like Receptor Agonists on Indoleamine-2,3-Dioxygenase-1 in Human Periodontal Ligament Stem/Stromal Cells.

  Behm C, Blufstein A, Gahn J, Kubin B, Moritz A, Rausch-Fan X, Andrukhov O. Behm C, et al. Cells. 2020 Dec 16;9(12):2696. doi: 10.3390/cells9122696. Cells. 2020. PMID: 33339125 Free PMC article.

• Modulation of T-Cell Activation Markers Expression by the Adipose Tissue-Derived Mesenchymal Stem Cells of Patients with Rheumatic Diseases.

  Kuca-Warnawin E, Janicka I, Szczęsny P, Olesińska M, Bonek K, Głuszko P, Kontny E. Kuca-Warnawin E, et al. Cell Transplant. 2020 Jan-Dec;29:963689720945682. doi: 10.1177/0963689720945682. Cell Transplant. 2020. PMID: 32878464 Free PMC article.

• The Phenotype and Secretory Activity of Adipose-Derived Mesenchymal Stem Cells (ASCs) of Patients with Rheumatic Diseases.

  Kuca-Warnawin E, Skalska U, Janicka I, Musiałowicz U, Bonek K, Głuszko P, Szczęsny P, Olesińska M, Kontny E. Kuca-Warnawin E, et al. Cells. 2019 Dec 17;8(12):1659. doi: 10.3390/cells8121659. Cells. 2019. PMID: 31861245 Free PMC article.

References

Publication types

LinkOut - more resources

• Full Text Sources

  • Baishideng Publishing Group Inc.
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database
  • scite Smart Citations